Lyka Labs Peer Comparison

NSE: LYKALABS | BSE: 500259

₹74.30

₹-0.96 (-1.28%)

As on 07-Oct-2026IST

Market cap

₹266 Cr

Revenue (TTM)

₹138 Cr

P/E Ratio

P/B Ratio

2.8

Div. Yield

0 %

Edit

	Lyka Labs	Dishman Carbogen	Take Solutions	Vivo Bio Tech	Genomic Biotech
Market cap (₹ Cr)	266	2,392	180	33	10
Revenue (₹ Cr)	138	2,901	85	55	0
Net Profit (₹ Cr)	-9.39	16.16	12.82	-2.86	0.02
Net Margin (%)	-6.66	0.55	6.38	-5.15	9.72
RoE (%)	-9.20	0.29	20.84	-16.06	0.53
Price to Earnings	--	148.00	14.06	--	468.94
Price-To-Book	2.82	0.36	5.62	0.36	2.50

Income Statement (₹ Cr)

	Lyka Labs	Dishman Carbogen	Take Solutions	Vivo Bio Tech	Genomic Biotech
Operating Revenue	128.44	2,931.90	54.19	53.33	0.84
Total Income	131.94	2,987.84	60.87	53.78	0.85
Total Expenditure	131.93	2,366.27	56.10	32.43	0.40
EBITDA	-3.49	565.63	-1.91	20.91	0.44
Depreciation	8.46	338.69	0.01	10.63	0.00
EBIT	-11.95	226.94	-1.92	10.28	0.44
Interest	3.33	174.18	0.35	5.91	0.00
Other Income	3.50	55.94	6.69	0.44	0.00
Exceptional Items	--	-3.80	--	--	--
Profit before Tax	-11.78	104.90	4.42	4.81	0.44
Provision for Tax	-1.34	7.45	0.16	6.52	0.09
Profit after Tax	-10.44	97.45	4.26	-1.71	0.36

	Lyka Labs	Dishman Carbogen	Take Solutions	Vivo Bio Tech	Genomic Biotech
Shareholder's Funds	92.39	6,676.90	31.00	93.16	3.90
Minority Interest	-1.56	--	0.00	--	--
Non-Current Liabilities	29.81	2,846.00	0.00	55.04	0.00
Current Liabilities	53.90	2,317.05	5.24	30.23	0.46
Total Liabilities	174.54	11,911.40	36.24	178.43	4.36

	Lyka Labs	Dishman Carbogen	Take Solutions	Vivo Bio Tech	Genomic Biotech
Non-Current Assets	111.26	8,997.85	12.48	149.74	1.73
Current Assets	63.28	2,842.10	23.77	28.42	2.62
Total Assets	174.54	11,911.40	36.24	178.43	4.36
Total Debt*	48.36	2,775.40	0.00	67.38	0.00
Net Current Assets	9.38	525.05	18.53	-1.82	2.16
Contingent Liabilities	37.44	428.74	--	--	--

	Lyka Labs	Dishman Carbogen	Take Solutions	Vivo Bio Tech	Genomic Biotech
Cash From Operating Activities	5.24	491.45	-4.13	34.93	0.03
Cash Flow from Investing Activities	-9.41	-245.34	1.74	-59.35	0.01
Cash from Financing Activities	4.19	200.58	-0.72	24.57	--
Net Cash Inflow / Outflow	0.02	446.69	-3.11	0.15	0.04

	Lyka Labs	Dishman Carbogen	Take Solutions	Vivo Bio Tech	Genomic Biotech
ROCE (%)	-5.96	3.21	18.49	7.34	11.87
ROE (%)	-10.64	1.56	16.52	-2.11	9.57
ROA (%)	-5.95	0.89	11.71	-1.06	8.20
EBIT Margin (%)	0.01	21.20	8.81	40.03	52.63
Net Margin (%)	-7.91	3.26	6.99	-3.18	41.97
Cash Profit Margin (%)	-1.54	14.88	7.87	16.72	42.50

	Lyka Labs	Dishman Carbogen	Take Solutions	Vivo Bio Tech	Genomic Biotech
Revenue Growth (%)	-7.26	8.13	-100.00	14.27	411.25
EBIT Growth (%)	-99.94	26.69	73.95	-15.82	2,529.91
Net Profit Growth (%)	-231.54	2,907.72	476.63	-123.46	2,245.51
EPS Growth (%)	-225.21	2,908.18	-71.28	-118.15	2,245.67
Book Value Growth (%)	-11.84	14.50	51.02	29.61	10.05

	Lyka Labs	Dishman Carbogen	Take Solutions	Vivo Bio Tech	Genomic Biotech
Price / Earnings	0.00	20.92	53.86	0.00	50.26
Price / Book Value	1.74	0.31	18.91	0.51	4.59
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	0.00	6.15	122.77	5.28	40.19
Market Cap (₹ Cr)	159.68	2,038.26	586.26	46.71	17.90

	Lyka Labs	Dishman Carbogen	Take Solutions	Vivo Bio Tech	Genomic Biotech
Debt to Equity	0.53	0.42	0.00	0.74	0.00
Short term debt to equity ratio	0.21	0.13	--	0.13	--
Current Ratio	1.17	1.23	4.54	0.94	5.73
Quick Ratio	0.92	0.79	4.54	0.67	5.11
Interest Coverage	-2.54	1.60	13.66	1.81	2,845.31

	Lyka Labs	Dishman Carbogen	Take Solutions	Vivo Bio Tech	Genomic Biotech
Debtors to sales (%)	27.28	22.95	0.40	22.03	262.40
Asset Turnover	0.73	0.27	1.49	0.33	0.19
Receivable days	110.99	83.29	1.47	78.69	1,026.01
Inventory Days	37.08	119.47	0.00	54.55	122.93
Payable days	115.42	197.26	9.35	66.07	554.30
Cash Conversion Cycle	32.64	5.50	-7.88	67.17	594.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.